hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 16:29:10 - browse：81

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Dana Farber says 6 studies to be retracted and 31 corrected

WSS

Mass General, Mayo Clinic look to monetize custom

CDC picks Alphabet's Verily for wasterwater surveillance contract

CDC picks Alphabet's Verily for wasterwater surveillance contract

Future doctors need a strong humanities education

Medicare innovation center doesn’t save money, experts say

TikTok, Instagram influencers need more rules for drug ads

hotspot

hotspot

leisure time

At least 13 dead in Texas as scorching temps continue

FDA endorses new sterilization method for medical devices

Walensky prepares to leave CDC — and Congress — behind

Dog Aging Project founders on what lies ahead after losing funding

Moonlake's readout produced a cash windfall. Risks remain

Setback for rare diseases as Taysha Gene Therapies pulls back

Heart attack and stroke risk calculators need revising

Congress extends some pandemic preparedness programs

After affirmative action ruling, medical educators look to 'holistic review'

There's an unseen cost to disruptive road

hotspot

HPV vaccine, cervical cancer study delivers historic results

Dana Farber says 6 studies to be retracted and 31 corrected

Dog Aging Project founders on what lies ahead after losing funding

Flu vaccine reformulation won't be easy, manufacturers warn

6 solutions to address cancer drug shortages and others

WHO recommends second malaria vaccine

entertainment

hotspot

focus

knowledge